Loading...

PTC Announces Translarna™ Approval in Russia for the Treatment of Duchenne Muscular Dystrophy

Print Friendly, PDF & Email

SOUTH PLAINFIELD, N.J., Dec. 4, 2020 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) has been granted marketing approval in the Russian Federation for nonsense mutation Duchenne muscular dystrophy (nmDMD). It is estimated that 13% of DMD patients have a nonsense mutation. In countries where […]